This short review highlights some recent advances in matrix metalloproteinase inhibitor (MMPi) design and development. Three distinct approaches to improved MMP inhibition are discussed: (1) the identification and investigation of novel zinc-binding groups (ZBGs), (2) the study of non-zinc-binding MMPi, and (3) mechanism-based MMPi that form covalent adducts with the protein. Each of these strategies is discussed and their respective advantages and remaining challenges are highlighted. The studies discussed here bode well for the development of ever more selective, potent, and well-tolerated MMPi for treating several important disease pathologies.
Fragment-based lead design (FBLD) has been used to identify new metal-binding groups for metalloenzyme inhibitors. When screened at 1 mM, a chelator fragment library (CFL-1.1) of 96 compounds produced hit rates ranging from 29-43% for five matrix metalloproteases (MMPs), 24% for anthrax lethal factor (LF), 49% for 5-lipoxygenase (5-LO), and 60% for tyrosinase (TY). The ligand efficiencies (LE) of the fragment hits are excellent, in the range of 0.4-0.8 kcal/mol. The MMP enzymes all generally elicit the same chelators as hits from CFL-1.1; however, the chelator fragments that inhibit structurally unrelated metalloenzymes (LF, 5-LO, TY) vary considerably. To develop more advanced hits, one hit from CFL-1.1, 8-hydroxyquinoline, was elaborated at four different positions around the ring system to generate new fragments. 8-Hydroxyquinoline fragments substituted at either the 5-or 7-positions gave potent hits against MMP-2, with IC 50 values in the low micromolar range. The 8-hydroxyquinoline represents a promising, new chelator scaffold for the development of MMP inhibitors that was discovered by use of a metalloprotein-focused chelator fragment library.
A chelator fragment library based on a variety of metal binding groups was screened against a metalloproteinase. Lead hits were identified and an expanded library of select compounds was synthesized, resulting in numerous high-affinity hits against several metalloprotein targets. The findings clearly demonstrate that chelators can be used to generate libraries suitable for fragmentbased lead design (FBLD) directed at important metalloproteins. Keywordschelators; fragment-based lead design; libraries; metalloproteins; zinc Fragment-based lead design (FBLD), sometimes referred to as fragment-based drug discovery (FBDD), is an increasingly important strategy for the discovery of biologically active compounds.[1] FBLD generally uses libraries consisting of modest collections (100-1000 compounds) of small molecular fragments (MW <300 amu) that are screened against targets of interest.[2] Although such fragments do not bind as tightly (K d values in the micro-to millimolar range) as more complex molecules, including those used in high-throughput screening (HTS) approaches, they can provide 'hits' that serve as efficient starting structures for the development of potent inhibitors. Fragments that bind to a target are identified, after which one of two approaches is generally pursued: a) a single fragment can be elaborated in order to obtain a tight binder; or b) multiple fragments binding at adjacent and distinct sites can be connected by an appropriate linker to obtain a potent inhibitor. Compared to HTS, FBLD is purported to have several advantages, including a more efficient exploration of chemically diverse space and higher ligand efficiencies.Although the application of FBLD to metalloprotein targets of medicinal interest has been described, [3] Matrix metalloproteinases (MMPs) represent one of the most well-established targets in the realm of metalloproteins. These zinc(II)-dependent enzymes have been extensively studied, and the development of MMP inhibitors (MMPi) has played an important role in the discovery of inhibitors for other zinc(II)-dependent metalloproteins, such as anthrax lethal factor (LF), histone deacetylases (HDACs), and others.[10] Indeed, the earliest application of FBLD to a metalloprotein target was directed at MMP-3.[3] Therefore, we focused our preliminary library screening efforts on MMPs, as a representative system for identifying fragments that would bind zinc(II) metalloproteins. Based on widely-reported criteria for fragment libraries, [2] an initial chelator fragment library (CFL-1) was assembled. A modest library containing 96 structural cores was prepared from chelators with two to four donor atoms for binding metal ions and sufficient solubility for screening ( Figure 1). The chelating groups included picolinic acids, hydroxyquinolones, pyrimidines, hydroxypyrones, hydroxypyridinones and salicylic acids, in addition to other compounds that are well-established components of metalloprotein inhibitors, such as hydroxamic acids and sulfonamides ( Figure 1). The CFL-1 librar...
TASK-1 is a two-pore domain potassium channel that is important to modulating cell excitability, most notably in the context of neuronal pathways. In order to leverage TASK-1 for therapeutic benefit, its physiological role needs better characterization; however, designing selective inhibitors that avoid the closely related TASK-3 channel has been challenging. In this study, a series of bis-amide derived compounds were found to demonstrate improved TASK-1 selectivity over TASK-3 compared to reported inhibitors. Optimization of a marginally selective hit led to analog 35 which displays a TASK-1 IC50 = 16 nM with 62-fold selectivity over TASK-3 in an orthogonal electrophysiology assay.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.